MoonLake reports $519.8M cash; initiates Phase 3 VELA in HS, positive FDA/EMA feedback for PsA Phase 3

MoonLake Immunotherapeutics

2024-Q2 EPS reported -$0.60

Q2 2024 cash, equivalents and short-term debt securities of $519.8M; cash runway to end-2026 unchanged.
R&D expenses $23.7M (up from $13.0M prior quarter) driven by new trial initiations; G&A $6.9M.
Phase 3 VELA program in hidradenitis suppurativa (HS) initiated; topline HiSCR75 primary endpoint expected mid-2025.
Positive FDA and EMA feedback on regulatory path for Phase 3 IZAR program in psoriatic arthritis; topline results expected end-2026.
Capital Markets Update on Sept 11; Phase 3 VELA TEEN in adolescent HS targeted for year-end 2024 initiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.